Literature DB >> 9575372

Benign mimics of prostatic adenocarcinoma on needle biopsy.

P B Gaudin1, V E Reuter.   

Abstract

Various benign processes can mimic prostatic adenocarcinoma on needle biopsy. These processes include glandular lesions such as adenosis, atrophy, VMGH, and BCH; inflammatory conditions such as acute and chronic or granulomatous prostatitis; and the effects of therapy such as external beam radiation or androgen deprivation. Normal benign prostate tissues including seminal vesicles, paraganglia, and ganglion cells may also be confused histologically with prostatic adenocarcinoma in needle biopsy specimens. With careful attention to architectural and cytologic features, these lesions can be readily distinguished from prostatic adenocarcinoma in most cases. In difficult cases, immunohistochemical studies using antibodies to PSA and high molecular weight cytokeratin (34 beta E12) have proved to be an invaluable adjunct in the differential diagnosis of prostatic adenocarcinoma on needle biopsy.

Entities:  

Mesh:

Year:  1997        PMID: 9575372

Source DB:  PubMed          Journal:  Anat Pathol        ISSN: 1056-5884


  3 in total

1.  DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy.

Authors:  A Paziewska; M Dabrowska; K Goryca; A Antoniewicz; J Dobruch; M Mikula; D Jarosz; L Zapala; A Borowka; J Ostrowski
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

2.  Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.

Authors:  Filip Ambrozkiewicz; Jakub Karczmarski; Maria Kulecka; Agnieszka Paziewska; Magdalena Cybulska; Michal Szymanski; Jakub Dobruch; Artur Antoniewicz; Michal Mikula; Jerzy Ostrowski
Journal:  Biomed Res Int       Date:  2020-05-05       Impact factor: 3.411

3.  A Deep Learning Model for Prostate Adenocarcinoma Classification in Needle Biopsy Whole-Slide Images Using Transfer Learning.

Authors:  Masayuki Tsuneki; Makoto Abe; Fahdi Kanavati
Journal:  Diagnostics (Basel)       Date:  2022-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.